Levi & Korsinsky has notified investors of a pending securities investigation into Teladoc Health following a second-quarter 2026 revenue shortfall that erased roughly a quarter of the company's market value. Teladoc reported consolidated revenue of $606.9 million, below consensus estimates that ranged from $615 million to $628 million, while its BetterHelp segment revenue fell 12% year-over-year to $212.6 million. The company also reduced its full-year 2026 revenue outlook to between $2.36 billion and $2.45 billion and slashed BetterHelp segment revenue growth expectations to a decline of 19% to 12.7%. Shares dropped around 29% intraday on the news. The investigation concerns potentially materially false or misleading statements about the company's forward revenue outlook, and shareholders who purchased TDOC and suffered losses may request a no-cost review of their recovery options.
Teladoc IncRevenue miss and guidance cut led to a 29% stock drop and securities investigation.
